- Home
- EML vs IKT Comparison
EML vs IKT Comparison
Compare EML & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EML | IKT |
|---|---|---|
| Founded | 1858 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 181.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EML | IKT |
|---|---|---|
| Price | $20.11 | $1.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 10.5K | ★ 428.3K |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | N/A |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $19.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.49 | $1.33 |
| 52 Week High | $30.72 | $4.20 |
Technical Indicators
Market Signals| Indicator | EML | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 53.05 |
| Support Level | $18.82 | $1.43 |
| Resistance Level | $20.86 | $1.57 |
| Average True Range (ATR) | 0.65 | 0.10 |
| MACD | 0.22 | 0.01 |
| Stochastic Oscillator | 67.85 | 73.81 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.